MHCC97H, HEP3B AND Huh7 UT, AZD8055 or AZD8055 + Compound #57. MHCC97H, HEP3B AND Huh7 UT, AZD8055 or AZD8055 + Compound #57

HCC tumors have poor prognosis and few therapeutic options. Here, Mulero-Sánchez et al. show that the combination of SHP2 inhibitors and mTOR inhibitor) effectively impairs tumor growth in vitro and in vivo. Overall design: Comparative gene expression profiling analysis of RNA-seq data for 3 different HCC human cell lines untreated or treated with AZD8055 or AZD8055 + Compound #57 (24-48h)